CD274 and gastric cancer: There is a great need for further high-quality studies, including additional data on different subtypes and larger randomized controlled trials, to confirm the efficacy and safety of alternative anti-PD-1/PD-L1 therapies for the treatment of patients with advanced GC/GEJC.